Background:Escherichia coli isolates displaying multidrug-resistance (MDR) are a major health care problem that results in mortality and morbidity. Integrons are DNA elements in E.coli that are related to antibiotic resistance. The aim of this study was to determine class 1 and 2 integrons and MDR in E. coli isolates obtained from patients in two Sanandaj hospitals, located in Iran. Materials and Methods: 120 isolates of E. coli were obtained from clinical specimens (from November 2013 to April 2014), and the susceptibility of E. coli antimicrobial agents was determined using the Kirby-Bauer disk diffusion method according to the CLSI. PCR were applied for detection of class 1 and 2 integrons in E. coli isolates. SPSS software v16 and the χ2 test were used for statistical analysis in order to calculate the association between antibiotic resistance and the presence of integrons (p < 0.05). Results: In a total of 120 E. coli isolates, 42.5% had MDR. Integrons were found in 50.9% of the MDR isolates, and included 47.05% class 1 and 3.92% class 2 integrons. The strains did not have both classes of integrons simultaneously. An association between resistance to antibiotics and integrons was found. Conclusion: Our results showed that int1 and int2 genes present in E. coli isolates obtained from patients cause MDR in this isolates. Since such bacteria are a reservoir for the transmission of MDR bacteria, appropriate programs are necessary to reduce this problem.

1.
Friedrich T, Rahmann S, Weigel W, Rabsch W, Fruth A, Ron E, Gunzer F, Dandekar T, Hacker J, Müller T, Dobrindt U: High-throughput microarray technology in diagnostics of enterobacteria based on genome-wide probe selection and regression analysis. BMC Genomics 2010;11:591.
2.
Japoni A, Gudarzi M, Farshad S, Basiri E, Ziyaeyan M, Alborzi A, Rafaatpour N: Assay for integrons and pattern of antibiotic resistance in clinical Escherichia coli strains by PCR-RFLP in Southern Iran. Jpn J Infect Dis 2008;61:85.
3.
Gastmeier P, Schwab F, Bärwolff S, Rüden H, Grundmann H: Correlation between the genetic diversity of nosocomial pathogens and their survival time in intensive care units. J Hosp Infect 2006;62:181-186.
4.
Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN: Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY antimicrobial surveillance program (1998-99). Diagn Microbiol Infect Dis 2002;42:193-198.
5.
Von Baum H, Marre R: Antimicrobial resistance of Escherichia coli and therapeutic implications. Int J Med Microbiol 2005;295:503-511.
6.
Rezaee MA, Sheikhalizadeh V, Hasani A: Detection of integrons among multi-drug resistant (MDR) Escherichia coli strains isolated from clinical specimens in the northwest of Iran. Braz J Microbiol 2011;42:1308-1313.
7.
Kargar M, Mohammadalipour Z, Doosti A, Lorzadeh S, Japoni-Nejad A: High prevalence of class 1 to 3 integrons among multidrug resistance diarrheagenic Escherichia coli in southwest of Iran. Osong Public Health Res Perspect 2014;5:193-198.
8.
Barlow RS, Pemberton JM, Desmarchelier PM, Gobius KS: Isolation and characterization of integron-containing bacteria without antibiotic selection. Antimicrob Agents Chemother 2004;48:838-842.
9.
Normark BH, Normark S: Evolution and spread of antibiotic resistance. J Intern Med 2002;252:91-106.
10.
Bass L, Liebert CA, Lee MD, Summers AO, White DG, Thayer SG, Maurer JJ: Incidence and characterization of integrons, genetic elements mediating multiple-drug resistance, in avian Escherichia coli. Antimicrob Agents Chemother 1999;43:2925-2929.
11.
Maguire AJ, Brown DF, Gray JJ, Desselberger U: Rapid screening technique for class 1 integrons in Enterobacteriaceae and nonfermenting Gram-negative bacteria and its use in molecular epidemiology. Antimicrob Agents Chemother 2001;45:1022-1029.
12.
Vinué L, Sáenz Y, Somalo S, Escudero E, Moreno MA, Ruiz-Larrea F, Torres C: Prevalence and diversity of integrons and associated resistance genes in faecal Escherichia coli isolates of healthy humans in Spain. J Antimicrob Chemother 2008;62:934-937.
13.
Collis CM, Hall RM: Site-specific deletion and rearrangement of integron insert genes catalyzed by the integron DNA integrase. J Bacteriol 1992;174:1574-1585.
14.
Leverstein-van Hall MA, Blok HE, Donders ART, Paauw A, Fluit AC, Verhoef J: Multidrug resistance among Enterobacteriaceae is strongly associated with the presence of integrons and is independent of species or isolate origin. J Infect Dis 2003;187:251-259.
15.
Schmitz F-J, Hafner D, Geisel R, Follmann P, Kirschke C, Verhoef J, Verhoef J, Köhrer K, Fluit AC: Increased prevalence of class I integrons in Escherichia coli, Klebsiella species, and Enterobacter species isolates over a 7-year period in a German university hospital. J Clin Microbiol 2001;39:3724-376.
16.
Fluit A, Schmitz FJ: Resistance integrons and super-integrons. Clin Microbiol Infect 2004;10:272-288.
17.
Yu G, Li Y, Liu X, Zhao X, Li Y: Role of integrons in antimicrobial resistance: a review. Afr J Microbiol Res 2013;7:1301-1310.
18.
Farshad S, Japoni A, Hosseini M: Low distribution of integrons among multidrug resistant E. coli strains isolated from children with community-acquired urinary tract infections in Shiraz, Iran. Polish J Microbiol 2008;57:193-198.
19.
Salem MM, Muharram M, Alhosiny IM: Distribution of classes 1 and 2 integrons among multi drug resistant E. coli isolated from hospitalized patients with urinary tract infection in Cairo, Egypt. Aust J Basic Appl 2010;4:398-407.
20.
Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing, 20th information supplement. M100-S20. CLSI, Wayne, 2010.
21.
Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M: Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clinl Infect Dis 2010;51:286-294.
22.
Rosser SJ, Young H-K: Identification and characterization of class 1 integrons in bacteria from an aquatic environment. J Antimicrob Chemother 1999;44:11-18.
23.
Ploy MC, Denis F, Courvalin P, Lambert T: Molecular characterization of integrons in Acinetobacter baumannii: description of a hybrid class 2 integron. Antimicrob Agents Chemother 2000;44:2684-2688.
24.
Phongpaichit S, Wuttananupan, Samasanti W: Class 1 integrons and multidrug resistance among Escherichia coli isolates from human stools. Southeast Asian J Trop Med Public Health 2008;39:279-278.
25.
Anvarinejad M, Farshad S, Alborzi A, Ranjbar R, Giammanco GM, Japoni A: Integron and genotype patterns of quinolones-resistant uropathogenic Escherichia coli. Afr J Microbiol Res 2011;5:3765-3770.
26.
El-Najjar NG, Farah MG, Hashwa FA, Tokajian ST: Antibiotic resistance patterns and sequencing of class I integron from uropathogenic Escherichia coli in Lebanon. Lett Appl Microbiol 2010;51:456-461.
27.
Rajabnia R, Asgharpour F, Ferdosi Shahandashti F, Khalilian M, Norkhomami S, Shafii M, Moulana Z: Class 1 integron in Pseudomonas aeruginosa isolates from different places and devices of ICU in Babol, Iran. Jundishapur J Microbiol 2013:6:138-143.
28.
Márquez C, Labbate M, Ingold AJ, Chowdhury PR, Ramírez MS, Centrón D, Borthagaray G, Stokes HW: Recovery of a functional class 2 integron from an Escherichia coli strain mediating a urinary tract infection. Antimicrob Agents Chemother 2008;52:4153-4154.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.